Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Cipla reports a significant Q4 profit rise despite concerns over US tariffs and drug price orders.
Cipla, an Indian pharmaceutical company, reported a 30% rise in Q4 net profit to Rs 1,222 crore and a 9% increase in revenue to Rs 6,730 crore.
The company's CEO, Umang Vohra, stated that potential US tariffs and Trump's order on drug prices are not expected to have an immediate impact on Cipla.
The company's board approved a dividend of Rs 16 per share, marking its 90th anniversary.
For FY25, Cipla saw a 28% increase in net profit to Rs 5,272 crore.
12 Articles
Cipla informa de un aumento significativo de las ganancias del cuarto trimestre a pesar de las preocupaciones sobre los aranceles estadounidenses y las órdenes de precios de medicamentos.